SEQUUS PHARMACEUTICALS, INC. – Trademark Portfolio

Entity Type: 03

SEQUUS PHARMACEUTICALS, INC. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. Currently, 1 trademark is registered. Notable registered marks include DOXIL. The owner is based in MENLO PARK, CA.

960 HAMILTON COURT

MENLO PARK, CA 94025

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

CELARIS
CELARIS
Abandoned 1998
CLANDIS
CLANDIS
Abandoned 1998
CAELYX
CAELYX
Abandoned 1997
ELIPCIN
ELIPCIN
Abandoned 1996
SEQUUS
SEQUUS
Cancelled 1995
AMPHOTEC
AMPHOTEC
Cancelled 1993
DOXIL
DOXIL
Registered 1991

Trademark Classifications

SEQUUS PHARMACEUTICALS, INC.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does SEQUUS PHARMACEUTICALS, INC. have?

SEQUUS PHARMACEUTICALS, INC. has 7 U.S. trademarks filed with the USPTO. Of these, 1 registered, 4 abandoned, 2 cancelled.

What trademark classes does SEQUUS PHARMACEUTICALS, INC. file in?

SEQUUS PHARMACEUTICALS, INC. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SEQUUS PHARMACEUTICALS, INC.'s most well-known trademarks?

SEQUUS PHARMACEUTICALS, INC.'s registered trademark portfolio includes well-known marks such as DOXIL. These are among 1 currently registered trademark in the portfolio.

What is SEQUUS PHARMACEUTICALS, INC.'s trademark registration success rate?

SEQUUS PHARMACEUTICALS, INC. has a 14% trademark registration rate, with 1 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.